🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million instances each year. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This milestone marks a significant shift in the therapy of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Outcomes and Worldwide Availability

According to results released by a major medical journal, the new drug eradicated over nine in ten of cases of the STI. This puts it on an similar efficacy with the typical regimen, which involves an injection and a pill. The trial involved over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Doctors treating patients have voiced positive views. Having a one-pill regimen like this is hailed as a "critical tool" for gonorrhoea control. This is considered essential to alleviate the strain of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.